Tocolysis cycle | Total | 1st | 2nd | 3rd | |
---|---|---|---|---|---|
Patients (n) | 309/509 cycles | 309 | 129 | 47 | |
Clinical findings | |||||
Preterm labor | 280 (55.0%) | 148 (47.9%) | 83 (64.3%) | 32 (68.1%) | |
Isolated CXI | 146 (28.7%) | 98 (31.7%) | 92 (71.3%) | 37 (78.7%) | |
PROM | 38 (7.5%) | 29 (9.4%) | 5 (3.9%) | 2 (4.3%) | |
Genital Infection | 20 (3.9%) | 13 (4.2%) | 4 (3.1%) | 3 (6.4%) | |
CX < 25 mm | 379 (74.5%) | 227 (73.5%) | 103 (79.8%) | 30 (63.8%) | |
Cervical length | 34.6 ± 51.9 | 36.06 ± 56.0 | 33.41 ± 48.2 | 31.43 ± 42.21 | |
Multiple prenancy | 148 (29.1%) | 78 (25.2%) | 42 (32.6%) | 21 (44.7%) | |
Indication for tocolysis | |||||
Lung maturation | 289 (56.8%) | 234 (75.7%) | 40 (31.0%) | 8 (17.0%) | |
Prolongation of pregnancy | 218 (42.8%) | 73 (23.6%) | 89 (69.0%) | 39 (83.0%) | |
Transfer to center | 2 (0.4%) | 2 (0.7%) | 0 (0.0%) | 0 (0.0%) | |
GA at beginning (weeks) | 28.32 ± 3.3 | 27.68 ± 3.5 | 29.09 ± 2.9 | 29.32 ± 2.7 | |
Duration of tocolysis (days) | 4.8 ± 6.3 | 4.78 ± 6.8 | 4.61 ± 5.7 | 4.63 ± 4.7 | |
Type | Atosiban | 439 (86.2%) | 263 (85.1%) | 115 (89.1%) | 39 (83.0%) |
Hexoprenaline | 43 (8.5%) | 30 (9.7%) | 8 (6.2%) | 5 (10.6%) | |
Nifedipine | 2 (0.4%) | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) | |
Switch of substance/double medication | 25 (4.9%) | 16 (5.2%) | 5 (3.9%) | 3 (6.4%) |